Middle East & Africa Stem Cell Therapy Market Forecast to 2028 - Regional Analysis - by Type, Treatment, Application, and End User

The Middle East & Africa Stem Cell Therapy Market is expected to grow from US$ 53.25 million in 2022 to US$ 96.12 million by 2028. It is estimated to grow at a CAGR of 10.3% from 2022 to 2028.

Increasing Research Activities Related to Stem Cell Therapy for Effective Disease Management Drive Middle East & Africa Stem Cell Therapy Market

Stem cell therapy has been widely investigated across the world. Stem cells are mainly used to replace dying cells and reconstruct damaged tissues. Based on the results of extensive stem cell research conducted so far, many scientists have claimed that these cells could probably be utilized to generate cures and treatments for diseases such as cancer and cardiovascular disease. Newly developed stem cell therapies involve replacing disease-causing cells with stem cells. Many potential treatments involving stem cells are in different phases of clinical trials. Researchers are further investigating the use of stem cell therapy in treating autoimmune disorders. For example, stem cells can turn into the cells of damaged organs and are used in treating autoimmune diseases. Treatment is carried out using mesenchymal stem cells or fetal stem cells. Hematopoietic stem cells are currently used for treating more than 80 medicals conditions, including immune system diseases, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and cancer types such as leukemia and lymphoma.

Middle East & Africa Stem Cell Therapy Market Overview

Research and development for stem cells in UAE are gaining a rapid pace. Moreover, devising strategic policies and an increasing number of research partnerships & collaborations are projected to offer lucrative opportunities for the growth of the UAE stem cell therapy market during the forecast period. For instance, in 2019, Dubai Healthcare City announced an increase in stem cell banking services. The hospital and ReGen Medical Management entered into a partnership to offer a range of specialty regenerative services in the UAE. By September 2019, the hospital conducted around 600 successful stem cell therapy procedures.

Increasing awareness of benefits served by stem cell therapies and to offer these novel therapeutics for the treatment of chronic conditions, a significant number of investors and industry players are entering into the Middle East & Africa Stem Cell Therapy Market market. For instance, in September 2019, BRS Group announced a plan to open a stem cell research company in Abu Dhabi. Such aforementioned factors are responsible for influential growth of stem cell therapy in the UAE thereby dominating the overall market growth during the forecast period.

Middle East & Africa Stem Cell Therapy Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Stem Cell Therapy Market Segmentation

The Middle East & Africa Stem Cell Therapy Market is segmented into type, treatment, application, end user, and country.

Based on type, the Middle East & Africa Stem Cell Therapy Market is segmented into adult stem cell therapy, embryonic stem cell therapy, induced pluripotent stem cell therapy, and other stem cell therapy. In 2022, the adult stem cell therapy segment registered a largest share in the Middle East & Africa Stem Cell Therapy Market. The adult stem cell therapy segment is further segmented into hematopoietic stem cell therapy, umbilical cord stem cell therapy, neuronal stem cell therapy, and mesenchymal stem cell.

Based on treatment, the Middle East & Africa Stem Cell Therapy Market is bifurcated into allogeneic and autologous. In 2022, the allogeneic segment registered a larger share in the Middle East & Africa Stem Cell Therapy Market.

Based on application, the Middle East & Africa Stem Cell Therapy Market is segmented into musculoskeletal, dermatology, cardiology, drug discovery & development, and other applications. In 2022, the musculoskeletal segment registered the largest share in the Middle East & Africa Stem Cell Therapy Market.

Based on end user, the Middle East & Africa Stem Cell Therapy Market is bifurcated into hospitals & specialty clinics and academic & research institutes. In 2022, the academic & research institutes segment registered a larger share in the Middle East & Africa Stem Cell Therapy Market.

Based on country, the Middle East & Africa Stem Cell Therapy Market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. In 2022, the UAE registered the largest share in the Middle East & Africa Stem Cell Therapy Market.

Lonza Group AG, Pluri Inc, Smith & Nephew Plc, and TiGenix NV (Takeda Pharmaceutical Company Limited) are the leading companies operating in the Middle East & Africa Stem Cell Therapy Market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA America stem cell therapy market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the MEA stem cell therapy market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the stem cell therapy market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution